Great Valley Advisor Group Inc. Acquires New Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Great Valley Advisor Group Inc. bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,782 shares of the medical equipment provider’s stock, valued at approximately $216,000.

Other institutional investors have also modified their holdings of the company. Naples Money Management LLC purchased a new position in Zimmer Biomet during the 4th quarter worth $35,000. Activest Wealth Management grew its holdings in Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 275 shares in the last quarter. Peoples Bank KS purchased a new position in Zimmer Biomet during the 3rd quarter valued at about $48,000. Blue Trust Inc. raised its holdings in shares of Zimmer Biomet by 48.4% in the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 153 shares in the last quarter. Finally, Quent Capital LLC lifted its position in shares of Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 92 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ZBH has been the topic of several recent research reports. TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. Evercore ISI boosted their target price on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Citigroup raised their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. boosted their price objective on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $135.40.

Insider Buying and Selling

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the transaction, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.70% of the stock is currently owned by insiders.

Zimmer Biomet Stock Down 0.9 %

ZBH stock opened at $120.57 on Tuesday. The company has a market capitalization of $24.80 billion, a P/E ratio of 26.10, a price-to-earnings-growth ratio of 2.23 and a beta of 1.03. The firm’s fifty day simple moving average is $125.17 and its 200-day simple moving average is $120.32. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $147.50. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.07. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The company’s revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the business posted $1.89 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend was Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.